linjc16/ctgov huggingface dataset:
Peritonitis and Loss of Residual Renal Function, Technique Failure and Mortality in Peritoneal Dialysis Patients

Study Overview
=================
Brief Summary
-----------------
The primary objective is to analyze peritonitis rate and peritonitis bacteriology as risk factors for loss of residual renal function, technique failure and mortality in chronic kidney disease patients. Secondary objectives are: To know the current rate of peritonitis in peritoneal dialysis population and to understand the bacteriological profile of peritonitis. To know the rate and risk factors other than peritonitis involved in the loss of residual renal function. To analyze the utility of alternative diagnostic tests, such as reagent strips, for early detection of peritonitis when traditional tests are not available. To analyze the simultaneous measurement of serum creatinine and cystatin-C as alternative measurements of peritoneal clearance and residual renal function.

Official Title
-----------------
The Role of Peritonitis in the Loss of Residual Renal Function, Technique Failure and Mortality in Peritoneal Dialysis Patients

Conditions
-----------------
Loss of Residual Renal Function, Technique Failure in Peritoneal Dialysis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:Inclusion criteria include: adult patients with signed informed consent given; there should not be selection for age, gender, primary cause of renal disease. - Exclusion Criteria:Patients will not be included if they were previously in hemodialysis or received renal transplant. Patients will also be excluded if they are on immunosuppressive therapy, have diagnosis of cancer, or are seropositive for HIV or hepatitis. -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Incident peritoneal dialysis patients<br>Patients with chronic kidney disease incident to peritoneal dialysis treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Loss of residual renal function |  | 25 months | 
| Technique (peritoneal dialysis) failure | Shift to hemodialysis | 25 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Peritonitis, loss of residual renal function, technique survival
Study Evaluating the Tolerability of Bifeprunox in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
Safety and tolerability study in healthy volunteers

Official Title
-----------------
A 3-Part, Randomized, Multiple-Dose, Sequential Design Study of Bifeprunox in Healthy Subjects in Order to Establish a Titration Regimen With an Improved Tolerability Profile

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: bifeprunox


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Healthy male 18-50 years Nonlactating female 18-50 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br>bifeprunox 25 day | Drug: bifeprunox<br>* oral tablet once daily<br>|
| Experimental: B<br>bifeprunox 14 day | Drug: bifeprunox<br>* oral tablet once daily<br>|
| Experimental: C<br>bifeprunox 14 day | Drug: bifeprunox<br>* oral tablet once daily<br>|
| Experimental: D<br>bifeprunox 9 day | Drug: bifeprunox<br>* oral tablet once daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tolerability |  | 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety |  | 28 days |
C1q/TNF-related Proteins in Non-Alcoholic Fatty Liver Disease

Study Overview
=================
Brief Summary
-----------------
Non-alcoholic fatty liver disease (NAFLD) is characterized by an accumulation of fat in the liver, which is one of the most common forms of chronic liver disease in developed countries. In western countries, the prevalence of NAFLD in the general population is estimated to be 20-30%; in obese populations, this increases to 57.5-74%. But, it hasn't been clearly elucidated yet regarding the underlying disease pathophysiology and treatmet strategy. Recently, members of the C1q/tumor necrosis factor-related protein (CTRP) family have been reported to share structural homology with adiponectin. To date, 15 CTRP family members have been found that might play major roles in glucose metabolism and inflammation. The investigators tried to clarify the relationship between CTRP family and NAFLD in Korean men and women.

Conditions
-----------------
NAFLD

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 20<age<80 apparently healthy subjects Exclusion Criteria: a history of CVD diabetes stage 2 hypertension malignancy severe renal or hepatic disease

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with NAFLD<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum concentration of CTRP-1, 3, or 9 in the subjects with/without NAFLD |  | at enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The relationships of serum CTRPs/adiponectin levels with cardiometabolic risk profiles |  | at enrollment |
Treating Amblyopia in Adults With Interactive Video Games

Study Overview
=================
Brief Summary
-----------------
Researchers are trying to determine whether interactive video game play, while wearing a patch over better-seeing eye, will improve subject reduced vision (amblyopia).

Detailed Description
-----------------
The purpose of this research is to determine whether amblyopia (reduced vision in one eye) in adults can be improved using interactive video game play. Study participation involves playing the video game Mario KartTM (provided by the study), while wearing a patch over their better-seeing eye. Participants are asked to play the game for a total of 40 hours over a one-month period. The primary outcome measure will be LogMAR visual acuity measured 1 month after initiating game play.

Official Title
-----------------
Treating Amblyopia in Adults With Interactive Video Games

Conditions
-----------------
Amblyopia

Intervention / Treatment
-----------------
* Other: Video game Mario Kart Wii


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged >17 years old Refraction within past year and wearing updated glasses or contact lenses Diagnosis of strabismic, anisometropic or combined amblyopia (> 2 lines inter-ocular difference) Stable visual acuity as defined as <1 LogMAR change over 2 visits 8 weeks apart, or wearing glasses for at least 16 weeks Exclusion Criteria: Monovision and unwilling to wear corrective glasses Allergy to adhesive bandages Women who are currently pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Subjects with Amblyopia<br>Adult amblyopia subjects will play the video game Mario Kart Wii | Other: Video game Mario Kart Wii<br>* Subjects will place a patch over the better-seeing eye and play the video game Mario Kart Wii for a total of 40 hours over a 1 month perior<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in visual acuity | measured using the LogMAR (Logarithm of the Minimum Angle of Resolution) chart comprised of rows of letters to estimate visual acuity | Baseline, one month |
Men's Beliefs About Associations Between HPV, Cancers, and HPV Vaccination

Study Overview
=================
Brief Summary
-----------------
This research focuses on men who have sex with men (MSM) who are at higher risk of anal cancer. The survey will evaluate their beliefs about anal and oral cancer, their knowledge about role of human papillomavirus (HPV) infection in these cancers, and their knowledge of HPV vaccination and anal Pap smears. Approximately 12% of subjects will be HIV-positive.

Detailed Description
-----------------
Little research has examined men's understanding of what causes anal and oral cancers and whether HPV vaccination can play a potential protective role. This research focuses on men who have sex with men (MSM) who are at notably elevated risk of anal cancer, and seeks to characterize their beliefs about anal and oral cancer, knowledge about the etiological role of HPV infection in these cancers, as well as their knowledge of HPV vaccination and anal Pap smears. We will also study heterosexual men.

Official Title
-----------------
Men's Beliefs About Associations Between HPV, Cancers, and HPV Vaccination

Conditions
-----------------
Anus Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male aged 18-59 answered question about sexual orientation Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 59 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Willingness to Receive the Human Papillomavirus (HPV) Vaccine | Measured participants' willingness to receive HPV vaccine. Participants were asked how willing they would be to get HPV vaccine if it were approved for use in males. A 5-point scale ranging from definitely not willing to definitely willing was used to meausure willingness. | at time of interview | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Awareness of HPV Vaccine | Measured if participants had heard of HPV vaccine prior to survey. Participants were asked if they had heard to HPV vaccine prior to the survey and had response options of yes, no, and I don't know. | At time of interview | 
| Knowledge of HPV | Assessed participants' knowledge of HPV by summing correct responses to nine HPV knowledge items. Questions addressed what diseases are associated with HPV, how HPV is transmitted, and how common HPV infection is. For each item, participants were classified as having answered the item correctly or incorrectly. | At time of interview |
Impact of %6 HES 130/0.4 and %4 Gelofusine Infusion on Kidney Function in the Living-donor Liver Transplantation

Study Overview
=================
Brief Summary
-----------------
Although the negative impacts of colloid solutions with high molecular weight on renal functions, combination of lower molecular weight colloid varieties with crystalloid solutions and its use during intraoperative period have been subject to current research. Since the first liver transplantation, pre-or post-transplantation renal problems are still among the main causes of mortality and morbidity. The aim of the study was to evaluate the effects of fluid replacement solutions used intraoperatively on renal functions in elective living-donor liver transplantation.This study was approved by the Ethics Committee of Hospital and all patients were informed and gave written consent. Participants were patients scheduled for elective living-donor liver transplantation. Patients with normal renal function were randomly allocated to infusion with 6% HES 130/0.4 (HES Group) and 4% Gelofusine (GEL Group). Blood samples were obtained before induction of anesthesia (baseline), at the end of the operation, and postoperative days 1 and 4. Different eGFR formulas using creatinine (MDRD, CKD-EPI, and Cockraud Gault) were used to calculate estimated glomerular filtration rates.

Conditions
-----------------
Patients Undergoing Liver Transplantation

Intervention / Treatment
-----------------
* Drug: %6 HES and %4 Gelofusine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -Normal kidney function Exclusion Criteria: anormal kidney function cadaveric transplantation emergency operation patients less than 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| %4 Gelofusine<br>patients administered %4 Gelofusine during liver transplantation | Drug: %6 HES and %4 Gelofusine<br> <br> |
| %6 HES<br>patients administered %6 HES during liver transplantation | Drug: %6 HES and %4 Gelofusine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| renal dysfunction |  | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality |  | 1 month |
A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess patient compliance with DuoTrav versus concomitant administration of Timolol 0.5% plus TRAVATAN in patients with open-angle glaucoma or ocular hypertension.

Official Title
-----------------
Compliance Study Comparing DuoTrav to TRAVATAN Plus Timolol Using the Dosing Aid

Conditions
-----------------
Open-angle Glaucoma, Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: Travoprost 0.004%/timolol 0.5% ophthalmic solution
* Drug: Travoprost ophthalmic solution, 0.004%
* Drug: Timolol maleate ophthalmic solution, 0.5%


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients with open-angle glaucoma or ocular hypertension; Other protocol-defined inclusion criteria may apply. Exclusion Criteria: Visual acuity worse than 0.60; Other protocol-defined exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: DuoTrav<br>One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months, as recorded by dosing aid | Drug: Travoprost 0.004%/timolol 0.5% ophthalmic solution<br>* One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months using the Dosing Aid<br>* Other names: DuoTrav;|
| Other: Travatan/Timolol<br>One drop Timolol in the study eye(s) once daily at 8 AM; one drop of Travatan in the study eye(s) once daily at 8 PM. Both products dosed for twelve months, as recorded by separate dosing aid for each product. | Drug: Travoprost ophthalmic solution, 0.004%<br>* One drop in the study eye(s) once daily at 8 PM for twelve months using the Dosing Aid<br>* Other names: TRAVATAN;Drug: Timolol maleate ophthalmic solution, 0.5%<br>* One drop in the study eye(s) once daily at 8 AM or twelve months using the Dosing Aid<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient compliance | Patient compliance will be measured with a dosing aid that records time and date of study drug administration | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Open-angle glaucoma or ocular hypertension
Comparison of Depth of Sedation Performance Between SedLine and Comparator Device During General Anesthesia

Study Overview
=================
Brief Summary
-----------------
The primary objective is to compare the performance of Masimo's SedLine and the comparator's device systems during surgery. Relative accuracy of the individual depth of sedation indices will be compared.

Official Title
-----------------
Comparison of Depth of Sedation Performance Between SedLine and Comparator Device During General Anesthesia

Conditions
-----------------
Anesthesia

Intervention / Treatment
-----------------
* Device: SedLine Vs Comparator Test Group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients 18 years old and older at the time of consent. ASA status I, II, or III. English-speaking subjects. Scheduled for surgical and non-surgical procedures scheduled under general anesthesia (Common procedures include but are not restricted to tonsillectomy, adenoidectomy, urological procedures, dental rehabilitation, orthopedic procedures, biopsies, audiogram, nuclear scans, gastroscopy, colonoscopy, etc.). Exclusion Criteria: Any deformities or devices that may prevent application of EEG Sensor to forehead with a proper fit. Subjects who are developmentally delayed. Subjects deemed not suitable for study at the discretion of the investigator.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SedLine Vs Comparator Test Group<br> | Device: SedLine Vs Comparator Test Group<br>* Subjects will receive electrodes that compare EEG signals between Masimo's SedLine system and the comparator's system.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of Sedation Indices Performance Across Anesthesia Range | The correlation was computed using 1 min average values between the PSi and the comparator's sedation index. | Duration of surgery |
To Demonstrate the Relative Bioavailability of Atenolol Tablets, 100 mg

Study Overview
=================
Brief Summary
-----------------
To demonstrate the relative bioavailability of atenolol tablets, 100 mg.

Official Title
-----------------
A Comparative Bioavailability Study of Atenolol Tablets, 100 mg

Conditions
-----------------
Angina, Hypertension

Intervention / Treatment
-----------------
* Drug: Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)
* Drug: Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: Positive test results for HIV or hepatitis B or C. Treatment for drug or alcohol dependence.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.) | Drug: Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)<br> <br> |
| Active Comparator: 2<br>Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical) | Drug: Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bioequivalence based on AUC and Cmax |  | 20 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Angina (Chest Pain), Hypertension